What do systematic reviews say?

Naloxone vs placebo

The review found no eligible studies for this question.

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Naloxone vs placebo

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Very low

Naloxone + oxycodone prolonged release tablets vs oxycodone

Naloxone + oxycodone prolonged release tablets showed no clear difference in adverse events compared with oxycodone prolonged‐released tablets (low certainty).

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  RR 1.01 [0.87, 1.18]
  3 studies · 362 participants
  Low

Naloxone + oxycodone prolonged release tablets vs oxycodone

It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  RR 0.68 [0.44, 1.06]
  3 studies · 362 participants
  Very low